Rhenman & Partners Asset Management AB raised its position in shares of FibroGen Inc (NASDAQ:FGEN) by 20.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 301,727 shares of the biopharmaceutical company’s stock after purchasing an additional 50,537 shares during the quarter. FibroGen accounts for 1.6% of Rhenman & Partners Asset Management AB’s investment portfolio, making the stock its 27th biggest holding. Rhenman & Partners Asset Management AB owned about 0.36% of FibroGen worth $13,964,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in FGEN. Raymond James & Associates raised its holdings in shares of FibroGen by 14.2% during the second quarter. Raymond James & Associates now owns 13,174 shares of the biopharmaceutical company’s stock worth $825,000 after acquiring an additional 1,640 shares in the last quarter. FMR LLC raised its holdings in shares of FibroGen by 22.9% during the second quarter. FMR LLC now owns 8,404,819 shares of the biopharmaceutical company’s stock worth $526,142,000 after acquiring an additional 1,566,040 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of FibroGen by 1.8% during the third quarter. Vanguard Group Inc. now owns 6,921,874 shares of the biopharmaceutical company’s stock worth $420,503,000 after acquiring an additional 125,186 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of FibroGen by 1,829.4% during the third quarter. Nisa Investment Advisors LLC now owns 6,174 shares of the biopharmaceutical company’s stock worth $375,000 after acquiring an additional 5,854 shares in the last quarter. Finally, MetLife Investment Advisors LLC raised its holdings in shares of FibroGen by 49.7% during the third quarter. MetLife Investment Advisors LLC now owns 51,056 shares of the biopharmaceutical company’s stock worth $3,102,000 after acquiring an additional 16,945 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

Several brokerages recently issued reports on FGEN. Stifel Nicolaus began coverage on FibroGen in a report on Monday. They set a “buy” rating and a $71.00 price objective for the company. Zacks Investment Research lowered FibroGen from a “buy” rating to a “hold” rating in a report on Tuesday, November 13th. BidaskClub upgraded FibroGen from a “hold” rating to a “buy” rating in a report on Saturday, December 22nd. Leerink Swann set a $84.00 price objective on FibroGen and gave the stock a “buy” rating in a report on Monday, October 15th. Finally, Mizuho reissued a “buy” rating and set a $74.00 target price on shares of FibroGen in a research report on Monday, December 17th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. FibroGen currently has an average rating of “Buy” and a consensus target price of $70.40.

In other FibroGen news, Director James A. Schoeneck sold 2,000 shares of the stock in a transaction on Thursday, February 7th. The shares were sold at an average price of $57.17, for a total transaction of $114,340.00. Following the transaction, the director now directly owns 29,700 shares of the company’s stock, valued at $1,697,949. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider K Peony Yu sold 3,422 shares of the stock in a transaction on Friday, December 14th. The stock was sold at an average price of $38.58, for a total transaction of $132,020.76. Following the transaction, the insider now directly owns 144,123 shares in the company, valued at $5,560,265.34. The disclosure for this sale can be found here. Insiders have sold 253,568 shares of company stock worth $11,967,598 over the last three months. Company insiders own 8.96% of the company’s stock.

FibroGen stock opened at $56.98 on Monday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.76 and a current ratio of 6.76. The firm has a market cap of $4.84 billion, a price-to-earnings ratio of -32.94 and a beta of 1.77. FibroGen Inc has a one year low of $37.27 and a one year high of $68.55.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.15). The business had revenue of $29.00 million for the quarter, compared to analyst estimates of $36.48 million. FibroGen had a negative return on equity of 24.59% and a negative net margin of 87.84%. FibroGen’s revenue for the quarter was down 28.6% compared to the same quarter last year. On average, sell-side analysts predict that FibroGen Inc will post -1.55 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2019/02/11/fibrogen-inc-fgen-holdings-increased-by-rhenman-partners-asset-management-ab.html.

FibroGen Profile

FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.

Further Reading: What is channel trading?

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.